Following the restructuring of Lifecare including the acquisition of the twooperational German subsidiaries Lifecare NanoBioSensors and LifecareLaboratories, the Lifecare Board of Directors, management, and key personnelhave conducted an inspiring and productive workshop in Mainz, Germany. Due to acurrent high demand for Covid PCR testing, Lifecare Laboratories experiences anextraordinarily high activity level, generating revenue, while LifecareNanoBioSensors has increased its operational capacity. We are planning foradditional expansion of employees at our Norwegian headquarter and our plannedtechnical pathway stays unchanged.
Read more in the Lifecare February newsletter:https://lifecare.attme.dev/news/information-from-lifecare-february-2022/
This is LifecareLifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).
Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.attme.dev,+47 40 05 90 40
This stock exchange announcement was published by Kine Hereid, InvestorRelations at Lifecare AS, on 28.02.22 at 09:00 CET.